Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1850

1.

Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data.

Yu AP, Wu EQ, Birnbaum HG, Emani S, Fay M, Pohl G, Wintle M, Yang E, Oglesby A.

Curr Med Res Opin. 2007 Sep;23(9):2157-69. Review.

PMID:
17669232
2.

Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study.

Balkrishnan R, Rajagopalan R, Camacho FT, Huston SA, Murray FT, Anderson RT.

Clin Ther. 2003 Nov;25(11):2958-71.

PMID:
14693318
3.

A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine.

Misurski D, Lage MJ, Fabunmi R, Boye KS.

Appl Health Econ Health Policy. 2009;7(4):245-54. doi: 10.2165/11318730-000000000-00000.

PMID:
19905038
4.

Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.

Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM.

Health Technol Assess. 2004 May;8(21):iii-iv, 1-182. Review.

5.

A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.

Borah BJ, Darkow T, Bouchard J, Aagren M, Forma F, Alemayehu B.

Clin Ther. 2009 Mar;31(3):623-31. doi: 10.1016/j.clinthera.2009.03.005.

PMID:
19393853
6.

Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus.

Maetzel A, Ruof J, Covington M, Wolf A.

Pharmacoeconomics. 2003;21(7):501-12.

PMID:
12696990
7.

Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy.

Lage MJ, Fabunmi R, Boye KS, Misurski DA.

Adv Ther. 2009 Feb;26(2):217-29. doi: 10.1007/s12325-009-0002-0. Epub 2009 Feb 14.

PMID:
19219409
8.
9.

Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.

Cooke CE, Lee HY, Tong YP, Haines ST.

Curr Med Res Opin. 2010 Jan;26(1):231-8. doi: 10.1185/03007990903421994.

PMID:
19921965
10.
11.

Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.

Sánchez-Reyes L, Fanghänel G, Yamamoto J, Martínez-Rivas L, Campos-Franco E, Berber A.

Clin Ther. 2004 Sep;26(9):1427-35.

PMID:
15531005
12.

Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research.

Pelletier EM, Smith PJ, Boye KS, Misurski DA, Tunis SL, Minshall ME.

Appl Health Econ Health Policy. 2008;6(2-3):103-12. doi: 10.2165/00148365-200806020-00003.

PMID:
19231904
13.

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. doi: 10.1016/j.clinthera.2008.08.006. Erratum in: Clin Ther. 2008 Oct;30(10):1937.

PMID:
18803987
18.

Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland.

Brändle M, Erny-Albrecht KM, Goodall G, Spinas GA, Streit P, Valentine WJ.

Int J Clin Pharmacol Ther. 2009 Aug;47(8):501-15.

PMID:
19640359
19.

Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.

Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL.

Clin Ther. 2006 Oct;28(10):1712-25; discussion 1710-1. Erratum in: Clin Ther. 2006 Nov;28(11):1968-9.

PMID:
17157128
20.

Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US.

Ray JA, Valentine WJ, Roze S, Nicklasson L, Cobden D, Raskin P, Garber A, Palmer AJ.

Diabetes Obes Metab. 2007 Jan;9(1):103-13.

PMID:
17199725

Supplemental Content

Support Center